

Appl. No. 10/027,603
Amendment dated June 1, 2004
Reply to Office Action of January 30, 2004

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

- 1-57. (canceled)
58. (withdrawn) A method of inhibiting endothelial cell proliferation, comprising contacting said cells with an EG-VEGF antagonist in an amount effective to inhibit cell proliferation.
- 59-61. (canceled)
62. (previously presented) An antagonist of EG-VEGF that inhibits EG-VEGF induced proliferation of adrenal cortex-derived endothelial cells.
- 63-79. (canceled)
80. (new) An antibody or antibody fragment that specifically binds EG-VEGF.
81. (new) The antibody or antibody fragment of claim 80, wherein the antibody or antibody fragment is a monoclonal antibody or monoclonal antibody fragment.
82. (new) The antibody or antibody fragment of claim 80, wherein the antibody or antibody fragment is a chimeric antibody or chimeric antibody fragment.
83. (new) The antibody or antibody fragment of claim 80, wherein the antibody is a humanized antibody or humanized antibody fragment.
84. (new) The antibody or antibody fragment of claim 80, wherein the antibody fragment is a Fab, Fab', F(ab')₂, or Fv fragment.
85. (new) The antibody of claim 81, wherein the monoclonal antibody is produced from hybridoma cells having ATCC accession number PTA-4119, PTA-4120, PTA-4121, or PTA-4122.

Appl. No. 10/027,603
Amendment dated June 1, 2004
Reply to Office Action of January 30, 2004

86. (new) The antibody of claim 85, wherein the antibody or antibody fragment is a humanized antibody or humanized antibody fragment.
87. (new) The antibody of claim 85, wherein the antibody or antibody fragment is a Fab, Fab', F(ab')₂, or Fv fragment.
88. (new) The antibody or antibody fragment of claim 80, wherein the antibody or antibody fragment inhibits EG-VEGF induced proliferation of endothelial cells.
89. (new) The antibody or antibody fragment of claim 85, wherein the antibody or antibody fragment is a humanized antibody or humanized antibody fragment.
90. (new) The antibody or antibody fragment of claim 89, wherein the antibody fragment is a Fab, Fab', F(ab')₂, or Fv fragment.
91. (new) The antibody or antibody fragment of claim 80, wherein the EG-VEGF is a native sequence EG-VEGF.
92. (new) The antibody or antibody fragment of claim 91, wherein the native sequence EG-VEGF is a human sequence.
93. (new) The antibody or antibody fragment of claim 81, wherein the EG-VEGF comprises an amino acid sequence of SEQ ID NO:2.
94. (new) A composition comprising the antibody or antibody fragment of claim 80 in admixture with a carrier.
95. (new) The composition of claim 94, wherein the carrier is a pharmaceutically acceptable carrier.
96. (new) The composition of claim 94, wherein the antibody or antibody fragment is a monoclonal antibody or monoclonal antibody fragment.
97. (new) The composition of claim 94, wherein the antibody or antibody fragment is a chimeric antibody or chimeric antibody fragment.

Appl. No. 10/027,603
Amendment dated June 1, 2004
Reply to Office Action of January 30, 2004

98. (new) The composition of claim 94, wherein the antibody or antibody fragment is a humanized antibody or humanized antibody fragment.
99. (new) The composition of claim 94, wherein the antibody or antibody fragment is a Fab, Fab', F(ab')₂, or Fv fragment.
100. (new) The composition of claim 96, wherein the monoclonal antibody is produced from hybridoma cells having ATCC accession PTA-4119, PTA-4120, PTA-4121, or PTA-4122.
101. (new) The composition of claim 100, wherein the antibody or antibody fragment is a humanized antibody or humanized antibody fragment.
102. (new) The composition of claim 100, wherein the antibody or antibody fragment is a Fab, Fab', F(ab')₂, or Fv fragment.
103. (new) The composition of claim 94, wherein the antibody or antibody fragment inhibits EG-VEGF induced proliferation of endothelial cells.
104. (new) An article of manufacture, comprising:
- (a) a container;
 - (b) a label on the container; and
 - (c) the composition of claim 95.